2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

2325 Making bone marrow transplantation safer with FLT3 inhibitor-enhanced conditioning

Samuel John Taylor, PhD, Catherine Jankovic2, Jacob C Wajnryb3, Lynn White4, Catherine Rinaldi, PhD5, Swathi-Rao Narayanagari6, Jo Duyvestyn, PhD7, Ulrich Steidl, MD, PhD8, Carolyn S. Grove, MBBS, PhD, FRACP, FRCPA9, Wallace Langdon, PhD10
1 Washington University in St Louis, St Louis, Missouri, United States
2 Albert Einstein College of Medicine, Bronx, New York, United States
3 Washington University in St Louis, St Louis, Missouri, United States
4 Washington University in St Louis, St Louis, Missouri, United States
5 University of Western Australia, Perth, Western Australia, Australia
6 Albert Einstein College of Medicine, Bronx, New York, United States
7 University of Western Australia, Perth, Western Australia, Australia
8 Albert Einstein College of Medicine, Bronx, New York, United States
9 Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia, University of Western Australia, Perth, Western Australia, Australia
10 University of Western Australia, Perth, Western Australia, Australia

Myeloablative conditioning regimens utilize high-intensity chemotherapy or total body irradiation (TBI) to eradicate host hematopoiesis and facilitate life-saving donor hematopoietic stem cell transplantation (HSCT). However, regimen-related toxicities—including other organ damage and secondary malignancies—severely restrict the clinical application of myeloablative conditioning. Targeted inhibition of hematopoietic-specific pathways offers a promising strategy to augment conditioning efficacy while lowering the required doses of cytotoxic agents. Here, we hypothesized that pharmacological FLT3 inhibition would synergize with reduced-intensity conditioning to improve hematopoietic stem cell transplantation (HSCT) outcomes.

In C57BL/6 mice, pre-treatment with the FLT3 inhibitor quizartinib (30 mg/kg) markedly synergized with cyclophosphamide and TBI, inducing robust bone marrow (BM) cellularity depletion (57% vs. 6% reduction with TBI alone, 6 days after exposure; p < [0.001]). Time-course flow cytometric and phospho-flow analyses demonstrated that quizartinib triggered a rapid and selective depletion of multipotent progenitors (MPPs; LSK CD48+,CD150-) following irradiation, subsequently precipitating a sequential loss across all hematopoietic stem and progenitor cell (HSPC) populations, including long-term HSCs (LT-HSCs; LSK CD48-, CD150+) and committed progenitor lineage cells (LK cells). This synergistic HSPC loss was found to be a drug class effect, as combining TBI with alternative FLT3 inhibitors, sorafenib (60 mg/kg) or gilteritinib (30 mg/kg), similarly induced profound depletion of BM cellularity and HSPCs. Crucially, histological evaluation revealed that FLT3 inhibition did not exacerbate non-hematopoietic tissue injury, with intestinal crypt epithelial apoptotic lesions and mitotic scores remaining indistinguishable between quizartinib- and vehicle-treated irradiated mice.

RNA sequencing of sorted LSK and LK cells collected 20 hours post-quizartinib administration revealed significant downregulation of key DNA repair genes, including Brca1, Brca2, Rad51, and Nbn, in both murine LSK cells and human CD34+ HSPCs. Consequently, ionizing radiation exposure in quizartinib-primed HSPCs induced prolonged gamma-H2AX foci formation, confirming impaired DNA repair kinetics and persistent DNA damage in these cells.

To evaluate transplantation efficacy, mice were conditioned with sublethal TBI ranging from 200 to 900 Rads with or without quizartinib, followed by transplantation of 2 million CD45.1 donor BM cells. Over a 4-month monitoring period, quizartinib-treated recipient mice demonstrated significantly higher multilineage donor chimerism across all TBI doses tested (peripheral blood donor chimerism at 15 weeks in 700 Rad exposed mice: 61% with quizartinib vs. 35% with vehicle; p < [0.001]) and achieved robust donor engraftment at radiation doses that were otherwise non-myeloablative in control mice.

In conclusion, FLT3 inhibition sensitizes host HSPCs to DNA-damaging conditioning by downregulating critical DNA repair pathways, resulting in enhanced host HSPC clearance without compounding systemic toxicity. These findings establish a strong rational basis for incorporating FLT3 inhibitors into reduced-intensity conditioning regimens to achieve superior donor engraftment while minimizing regimen-related toxicity. If successful, this approach represents a paradigm shift, moving from dose-escalation towards a molecular sensitization framework that will be safer for all transplant patients and expand eligibility to elderly patients and those with underlying health conditions.

Samuel John Taylor, PhD: No relevant conflicts of interest to declare.